Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting

Confirmed Objective Response Rate of 47 Percent, with Responses Observed in Nine Unique Cancer Types Median Duration of Response Not Reached at 13 Months Median Follow-Up, with 11 of 15 Responses Ongoing Safety Consistent with Known Profile of Retevmo New Data Expands on Retevmo's Established Data